3585-60-2

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Isopropoxy-phenyl)-propionic acid is used as an analgesic for its pain-relieving properties, making it suitable for conditions that involve discomfort or pain.
2-(4-Isopropoxy-phenyl)-propionic acid is used as an antipyretic to reduce fever, helping to regulate body temperature in cases of elevated heat due to illness or other causes.
2-(4-Isopropoxy-phenyl)-propionic acid is used as an anti-inflammatory agent to minimize inflammation, often recommended for treating conditions such as arthritis, menstrual cramps, and minor injuries.
2-(4-Isopropoxy-phenyl)-propionic acid is utilized in over-the-counter medications, available in various forms like tablets, capsules, and liquid formulations for consumer convenience and accessibility.
2-(4-Isopropoxy-phenyl)-propionic acid is used with caution due to potential side effects and interactions with other drugs, requiring guidance from healthcare professionals for safe and effective use.

Upstream product

• 158816-13-8 (R,S)-2-<4-(isopropoxy)phenyl>propanoic acid methyl ester 
• 938-96-5 2-(4-Hydroxy-phenyl)-propionic acid 
• 65784-33-0 methyl 2-(4-hydroxyphenyl)propanoate 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 29056-05-1 methyl 2-(4-isopropoxyphenyl)acetate 

Downstream Products

• 110319-81-8 N-Hydroxy-2-(4-isopropoxy-phenyl)-N-methyl-propionamide 

Relevant academic research and scientific papers

2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors

The CXC chemokine CXCL8/IL-8 plays a major role in the activation and recruitment of polymorphonuclear (PMN) cells at inflammatory sites. CXCL8 activates PMNs by binding the seven-transmembrane (7-TM) G-protein-coupled receptors CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2). (R)-Ketoprofen (1) was previously reported to be a potent and specific noncompetitive inhibitor of CXCLS-induced human PMNs chemotaxis. We report here molecular modeling studies showing a putative interaction site of 1 in the TM region of CXCR1. The binding model was confirmed by alanine scanning mutagenesis and photoaffinity labeling experiments. The molecular model driven medicinal chemistry optimization of 1 led to a new class of potent and specific inhibitors of CXCL8 biological activity. Among these, repertaxin (13) was selected as a clinical candidate drug for prevention of post-ischemia reperfusion injury.

In Vivo Characterization of Hydroxamic Acid Inhibitors of 5-Lipoxygenase

The hydroxamic acid functionality can be incorporated into simple molecules to produce potent inhibitors of 5-lipoxygenase.The ability of many of these hydroxamates to inhibit leukotriene synthesis in vivo has been measured directly with a rat peritoneal anaphylaxis model.Despite their potent enzyme inhibitory activity in vitro, many orally dosed hydroxamic acids only weakly inhibited leukotriene synthesis in vivo.This discrepancy is attributable at least in part to the rapid metabolism of hydroxamates to the corresponding carboxylic acids, which are inactive against the enzyme.A study of the structural features that affect this metabolism revealed that 2-arylpropionohydroxamic acids are relatively resistant to metabolic hydrolysis.Several members of this class of hydroxamates are described that are orally active inhibitors of leukotriene synthesis.